TORONTO JDMI

University of Toronto
Sinai Health System
University Health Network
Women's College Hospital

UNIVERSITY OF TORONTO

MRI FEATURES PREDICTIVE OF RESPONSE TO METHOTREXATE AND VINORELBINE IN DESMOID FIBROMATOSIS

SALLY M. BURTENSHAW[1], ANA M. OLTEANU[1], REBECCA A. GLADDY[1], ABHA A. GUPTA[3], AND SENG THIPPHAVONG[2]

1. Division of General Surgery, Mount Sinai Hospital; Department of Surgical Oncology, Princess Margaret Cancer Centre; Department of Surgery University of Toronto, Toronto Ontario. 2. Toronto Joint Department of Medical Imaging, University Health Network, Sinai Health System and Women's College Hospital; Department of Medical Imaging, University of Toronto, Toronto Ontario. 3. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre

INTRODUCTION

- Desmoid fibromatosis (DF) is a mesenchymal tumor that is locally aggressive and historically treated with surgical resection, with high recurrence rates[1]

- Systemic treatment of progressive DF can be associated with improved progression-free rates; however, the use of medical therapy remains controversial

- Treatment response as defined by RECIST by measuring maximum tumor dimension (Dmax) may not accurately evaluate response to medical treatment in desmoid patients

INTRODUCTION

- Recent studies suggests alternatives to RECIST criteria[2]
- The current study sought to assess if imaging parameters such as approximate tumor volume (V_{tumor}) and MRI features, specifically T2 signal, were more predictive of response to medical therapy than D_{max}

INTRODUCTION



T2-fat-saturated coronal MR images of DF pre- and post-treatment

METHODS

- Using our Sarcoma Database, 22 patients with biopsy proven DF as per WHO Classification[3] who were treated with Methotrexate and Vinorelbine (MTX/VIN) and followed with MRI throughout treatment were identified

- Dmax, Vtumor and quantitative T2 hyperintensity using interquartile range scoring on MRI were compared pre-, mid- (between 3-9 months) and post-treatment

- On T2-weighted or T2-weighted fat-saturated MRI images, tumors were ranked as containing: 0-25%, 25-50%, 50-75% or 75-100% of internal high T2-signal intensity

METHODS

- V_{tumor} was approximated using an elliptical volume equation ($V=\pi/6*L*W*H$)

- Treatment response was defined as:

  Partial Response (PR) - size or T2 quartile score decreased

  Stable Disease (SD) - no change in size or T2 quartile

  Progression of Disease (PD) - increase in size or T2 quartile

  Complete Response (CR) – tumor resolution and/or entire lesion was hypointense on T2-weighted images

RESULTS

Patient Population	
	Number (%)
Gender	
Male	5 (23)
Female	17 (77)
Median Age [range]	31 [14-63]
Presentation	
Primary	18(82)
Recurrent/Residual	4 (18)
Tumor Site	
Extremity	9(41)
Abdominal wall	7(32)
Head and Neck	3(13)
Chest wall/back	2(9)
Mesentery	1(5)

Treatment	
	Number (%)
MTX/VIN regimen	
Day 1, 8, q21	2 (9)
Day 1, 8, 15, q28	20 (91)
NSAIDS tried before chemo	
Yes	2 (9)
No	20 (91)
Tamoxifen tried before chemo	
Yes	9 (41)
No	13 (59)
Previous Surgery	
Yes	4(18)
No	18(82)

RESULTS

- Patients were given 25mg/m^2 each of MTX/VIN
- Median months on treatment was 20 (range 9-27)
- Good clinical response (n=13), full therapy of 24 months reached (n=6), and patient preference (n=3) were reasons for stopping therapy

Dmax and Vtumor:

- At end of treatment (median 20 mos (range 9-27)), Dmax mean decreased by -30% and Vtumor decreased by -76%
- 50% of patients (n=11) had SD as per Dmax but were PR as per Vtumor %change (-76%, range -86 to-30)
- In those 11 patients, T2 showed CR in 6 patients and PR in 5 patients

Dmax and Vtumor:

Pre-tx Dmax did not show a response to treatment whereas Vtumor decreased as did T2 intensity.



Figure 2: T2-fat-saturated sagittal and coronal MRI images of DF in L foot pre- (Figures A and B) and post (Figures C and D) MTX/VIN.

T2 RESPONSE

- On T2-weighted imaging, CR was observed in 13 and PR in 5 patients
- Mid-treatment, 2 had PD and 7 patients had SD as per Dmax and Vtumor with T2 change indicative of PR in all cases
- Both patients with PD continued therapy and had CR at end of treatment
- Four patients progressed post-treatment, median Progression Free Survival (PFS) was 31 months (95% CI: 14.9-137), and all had complete response (CR) at the end of MTX/VIN treatment on T2 imaging

T2 RESPONSE



T2-fat-saturated (A) and T1-post-contrast (B) axial MR images of abdominal wall DF pre-treatment demonstrates high T2 signal and avid enhancement. Post treatment T2-fat-saturated and T1-post-contrast (C and D) showed decreased size and enhancement of DF.

T2 RESPONSE



T2 signal intensity pre-, mid- and post- MTX/VIN treatment

DISCUSSION

- Assessment of response to MTX/VIN with Dmax in patients with DF is problematic as longest axis of tumor may not change
- Estimated volume of tumor shows greater response to therapy than Dmax for half of the patients in the study
- T2 signal intensity assessment mid-treatment may be more indicative of response than RECIST, resulting in continued therapy for patients who may benefit

CONCLUSION

- Evaluation of treatment response for DF utilizing an estimated volume of tumor and monitoring the degree of T2-weighted signal intensity change within the tumor may be better predictors of response to medical therapy than maximum tumor dimension

- Findings from this study warrant prospective multi-institutional validation

ACKNOWLEDGEMENTS

We would like to express our thanks to our patients and the Jim Chamberlain Sarcoma Research Fund for the continued support of the clinical research program at Mount Sinai Hospital/Princess Margaret Cancer Centre.

REFERENCES

1. Deep (Desmoid-Type) Fibromatoses. In: Weiss SW, Folpe, AL, Goldblum JR eds. Enzinger &Weiss' Soft Tissue Tumors. Philadelphia, PA: Elsevier Saunders, 2014; 288-300.

2. Sheth PJ, et al. Desmoid fibromatosis: MRI features of response to systemic therapy. Skeletal Radiol (2016) 45:1365-1373.

3. Fletcher CDM, Bridge JA, Hogendoorn P., and Mertens F., eds. *WHO Classification of Tumours of Soft Tissue and Bone*. 4th ed. Lyon: International Agency For Research on Cancer, 2013.